<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LOMUSTINE</span><br/>(loe-mus'teen)<br/><span class="topboxtradename">CeeNU, </span><span class="topboxtradename">CCNU<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 40 mg, 100 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Lipid-soluble alkylating nitrosourea with actions like those of carmustine (e.g., cell-cycle-nonspecific activity against
         rapidly proliferating cell populations).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits synthesis of both DNA and RNA; has antineoplastic and myelosuppressive effect.</p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative therapy in addition to other modalities or with other chemotherapeutic agents in primary and metastatic brain tumors
         and as secondary therapy in Hodgkin's disease.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>GI, lung, and renal carcinomas, non-Hodgkin's lymphomas, malignant melanoma, and multiple myelomas.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Immunization with live virus vaccines, viral infections. Safe use during pregnancy (category D) or lactation is not established.
         Reported to be carcinogenic in laboratory animals.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with decreased circulating platelets, leukocytes, or erythrocytes; kidney or liver function impairment; infection;
         previous cytotoxic or radiation therapy.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Palliative Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 130 mg/m<sup>2</sup> as single dose, repeated in 6 wk; subsequent doses based on hematologic response (WBC &gt;4000/mm<sup>3</sup>, platelets &gt;100,000/mm<sup>3</sup>)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 75150 mg/m<sup>2</sup> q6wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach to reduce possibility of nausea, may also give an antiemetic before drug to prevent nausea.</li>
<li>Store capsules away from excessive heat (over 40° C).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Lethargy, ataxia, disorientation. <span class="typehead">GI:</span> Anorexia, <span class="speceff-common">nausea, vomiting,</span> stomatitis, transient elevations of LFTs. <span class="typehead">Hematologic:</span> Delayed (cumulative) myelosuppression: (<span class="speceff-life">thrombocytopenia, leukopenia</span>); anemia. <span class="typehead">Skin:</span> Alopecia, skin rash, itching. <span class="typehead">Urogenital:</span> Nephrotoxicity. <span class="typehead">Respiratory:</span> Pulmonary toxicity (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Cimetidine</b> can increase bone marrow toxicity; <span class="classification">anticoagulants</span>, <span class="classification">nsaid</span>s, <span class="classification">salicylates</span> increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 16 h. <span class="typehead">Distribution:</span> Readily crosses bloodbrain barrier; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to several active metabolites. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1648 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor blood counts weekly for at least 6 wk after last dose. Liver and kidney function tests should be performed
            periodically.
         </li>
<li>A repeat course is not given until platelets have returned to above 100,000/mm<sup>3</sup> and leukocytes to above 4000/mm<sup>3</sup>.
         </li>
<li>Avoid invasive procedures during nadir of platelets.</li>
<li>Thrombocytopenia occurs about 4 wk and leukopenia about 6 wk after a dose, persisting 12 wk.</li>
<li>Inspect oral cavity daily for S&amp;S of superinfections (see Appendix F) and stomatitis or xerostomia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Nausea and vomiting may occur 35 h after drug administration, usually lasting less than 24 h.</li>
<li>Anorexia may persist for 2 or 3 d after a dose.</li>
<li>Notify physician of signs of sore throat, cough, fever. Also report unexplained bleeding or easy bruising.</li>
<li>Use reliable contraceptive measures during therapy.</li>
<li>Be aware of the possibility of hair loss while taking this drug.</li>
<li>A given dose may include capsules of different colors; the pharmacist prepares prescribed dose by combining various capsule
            strengths.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>